ClostraBio

Biotechnology company developing engineered probiotics to support gut barrier function and treat lower gastrointestinal conditions, leveraging novel bacterial engineering approaches.

Location
Chicago, Illinois, USA
Founded
2018
Investors
1
Categories
biotech, microbiome, gut-health, probiotics, therapeutics

Notes

ClostraBio is a biotechnology company developing engineered probiotics designed to support gut barrier function and treat lower gastrointestinal issues. The company spun out of research from the University of Chicago and is developing novel approaches to modulate the gut microbiome for therapeutic benefit.

Their technology platform enables the engineering of beneficial bacteria to produce therapeutic molecules that strengthen the gut barrier and address conditions affecting the lower GI tract.

Team

  • Ritu Shah - Chief Executive Officer
  • Eugene Chang, M.D. - Scientific Founder (University of Chicago)

Additional Research Findings

  • Portfolio company of Portal Innovations
  • Stage: Pre-clinical
  • University Spinout: University of Chicago
  • Engineered probiotics for gut health
  • Focus on gut barrier function
  • Lower GI tract therapeutic applications
  • Chicago, Illinois headquarters
  • Microbiome-based therapeutic approach

Sources

Investors

NameLocationTypeStagesPortfolio
Portal InnovationsUSbiotech-focused-13